A part of Watch Media

Monday29 May 2023

Monday29 May 2023

28/05/2021at 14:59

Top news from MedWatch this week

Miss anything?

Photo: MedWatch

BY MIKKEL AABENHUS HEMMINGSEN

Tuesday

Novo Nordisk launches smart insulin pen in Denmark

Genmab partner gets approval for lung cancer drug from Duobody platform

Wednesday

New regulation means stricter requirements for medtech firms

Novo Holdings contributes to USD 540m investment in US health platform

Thursday

New sales agreement is another piece of Bavarian Nordic's commercial puzzle

Novo Holdings completes third investment in Asia in one month

Friday

Novo Nordisk risks insulin shock on Chinese market

Travel restrictions bite Bavarian as rabies vaccine sales plunge

Novo Nordisk successfully prices Euro medium term notes worth EUR 1.3bn

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Demant is fighting tooth and nail to get rid of its surgical division

Demant proposes partial Oticon Medical divestment to ease competition concerns

An analyst at investment bank ABG assesses that Demant has a tough nut to crack in closing the Oticon Medical divestment as originally envisioned.

For subscribers

CHMP recommends two drugs in May

For subscribers

Foto: MedWatch

Top news from MedWatch this week

According to GN, there has only been few cases of infection in the company's market organization | Foto: Pr

GN considers Covid-19 situation far less critical than six months ago

For subscribers

Foto: Novo Nordisk / Pr

Pharma & biotech

Novo Nordisk wins EU recommendation for label extension of long-acting growth hormone

For subscribers

Foto: Pool New/Reuters/Ritzau Scanpix

Pharma & biotech

Novo Nordisk's semaglutide shows potential against addiction

For subscribers

Further reading

Foto: Pool New/Reuters/Ritzau Scanpix

Pharma & biotech

Novo Nordisk's semaglutide shows potential against addiction

An analyst says it’s too early to say whether Novo Nordisk’s ”golden molecule” has commercial potential to treat addiction, however.

For subscribers

Demant is fighting tooth and nail to get rid of its surgical division

Demant proposes partial Oticon Medical divestment to ease competition concerns

An analyst at investment bank ABG assesses that Demant has a tough nut to crack in closing the Oticon Medical divestment as originally envisioned.

For subscribers

Researchers fear losing support for their research if making any critical statement about the Novo Nordisk Foundation | Foto: Novo Nordisk Fonden / Pr

Researchers fear falling from favor with Novo Nordisk Foundation

A string of researchers fear losing support for their work if they publicly criticize the Novo Nordisk Foundation, writes Danish news outlet.

For subscribers

Jobs